{"title":"卡培他滨治疗中引起皮肤毒性的患者不依从性","authors":"L. Kogoniya, K. E. Borisov, K. I. Ershova","doi":"10.17650/2782-3202-2022-2-3-55-58","DOIUrl":null,"url":null,"abstract":"When using capecitabine, manifestations of toxicity in the form of palmar-plantar dysesthesia, redness, excessive sensitivity and peeling of the skin of the palms and feet are well known. However, in the scientific literature available to us, we did not find a single case of skin toxicity with capecitabine, in contrast to targeted therapy, for which skin manifestations are very characteristic. The dermal toxicity described in this paper developed as a result of patient noncompliance. These side effects reduced the adherence to therapy: the next courses of chemotherapy were postponed.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"734 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patient noncompliance as the cause of skin toxicity in capecitabine therapy\",\"authors\":\"L. Kogoniya, K. E. Borisov, K. I. Ershova\",\"doi\":\"10.17650/2782-3202-2022-2-3-55-58\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"When using capecitabine, manifestations of toxicity in the form of palmar-plantar dysesthesia, redness, excessive sensitivity and peeling of the skin of the palms and feet are well known. However, in the scientific literature available to us, we did not find a single case of skin toxicity with capecitabine, in contrast to targeted therapy, for which skin manifestations are very characteristic. The dermal toxicity described in this paper developed as a result of patient noncompliance. These side effects reduced the adherence to therapy: the next courses of chemotherapy were postponed.\",\"PeriodicalId\":318498,\"journal\":{\"name\":\"MD-Onco\",\"volume\":\"734 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MD-Onco\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/2782-3202-2022-2-3-55-58\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MD-Onco","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/2782-3202-2022-2-3-55-58","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Patient noncompliance as the cause of skin toxicity in capecitabine therapy
When using capecitabine, manifestations of toxicity in the form of palmar-plantar dysesthesia, redness, excessive sensitivity and peeling of the skin of the palms and feet are well known. However, in the scientific literature available to us, we did not find a single case of skin toxicity with capecitabine, in contrast to targeted therapy, for which skin manifestations are very characteristic. The dermal toxicity described in this paper developed as a result of patient noncompliance. These side effects reduced the adherence to therapy: the next courses of chemotherapy were postponed.